[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$819share
Replimune's stock ($819share) fell sharply after the FDA rejected its application for RP1. The company plans to meet with the FDA to discuss a path forward.
About $819share
Social media activity related to the stock ticker $819share, likely representing a specific company.
Engagements: XX #
Engagements 24-Hour Chart Data
Current Value: XX
Daily Average: XXXXX
1-Year High: XXXXXX on 2025-07-22
1-Year Low: XX on 2025-07-27
| Social Network | X |
|---|---|
| Engagements | XX |
Mentions: X #
Mentions 24-Hour Chart Data
Current Value: X
Daily Average: X
1-Year High: X on 2025-07-22
1-Year Low: X on 2025-07-22
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Chart Data
X unique social accounts have posts mentioning $819share in the last XX hours which is no change from in the previous XX hours
Daily Average: X
1-Year High: X on 2025-07-22
1-Year Low: X on 2025-07-22
Top topics mentioned In the posts about $819share in the last XX hours
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$REPL $XXXX filled a few plummeted (-75%) $XXXXX to $XXXX on FDA response letter Current Cash $8.19/share Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma. The Company will request a Type A meeting and expects it will be granted within XX days. Replimune plans to urgently interact with the FDA to find a path forward for the timely accelerated approval Possible Reversal Play Manage Risks"
@TheBull_Stocks on X 2025-07-22 14:53:58 UTC 20.9K followers, 11.9K engagements